Rapamycin for longevity: what the human evidence actually shows
Rapamycin is a drug that reliably makes mice live longer, and some people now take it off-label for that reason. This guide covers what has and hasn't been shown in humans, the real risks of taking an immunosuppressant when you don't need one, and who should never consider it.
Rapamycin is the most reproducible lifespan-extending drug in mice, which is why it dominates longevity discourse — but the only 48-week randomised, placebo-controlled trial in healthy adults (PEARL, n=129) missed its primary endpoint entirely. It met its safety objective, meaning low-dose intermittent dosing appears tolerable over a year. That is a real finding. It is not evidence the drug slows human aging, and it is dispensed off-label, largely as a compounded product, by telehealth companies that profit from the prescription.
- PEARL — the only randomised placebo-controlled human trial — ran 129 healthy adults on 5 mg or 10 mg weekly for 48 weeks. Visceral adiposity, its primary endpoint, did not change (η² = 0.001, p = 0.942).
- Its positive secondary findings were sex-stratified, dose-stratified and partly self-reported — signals that need replication, not a demonstrated effect.
- The trial's sponsor, AgelessRx, is a telehealth company that sells rapamycin. That doesn't make the data wrong; it means it isn't independent.
- Rapamycin is FDA-approved as an immunosuppressant, for renal-transplant rejection prophylaxis. That mechanism is exactly what's being repurposed for longevity, and it carries real risk in someone who isn't a transplant patient.
- Compounded rapamycin — how most people taking it off-label actually get it — has different bioavailability from the approved generic, which is why a dedicated study (NCT06550271) exists just to characterise that gap.
What rapamycin actually does, and why mice live longer on it
Rapamycin allosterically inhibits mTORC1, a protein complex that senses amino acids, glucose and growth signals and, when active, drives cell growth and protein synthesis. Suppress it, and cells shift toward autophagy — clearing damaged proteins and organelles — and away from the growth programmes that geroscience links to age-related decline.
Across essentially every mouse strain and dosing regimen tested, mTOR inhibition extends lifespan. That consistency is unusual in aging biology and is the reason rapamycin is treated as the field's best-validated target — but a mechanism that works reliably in a short-lived model organism is a hypothesis in humans, not a result, until a human trial with a clinical endpoint says otherwise.
Rapamycin and its analogues, what each is actually approved for
| Drug | Class | Approved for | Longevity use |
|---|---|---|---|
| Rapamycin (sirolimus) | mTORC1 inhibitor | Renal-transplant rejection prophylaxis, lymphangioleiomyomatosis | Off-label, largely compounded, dispensed by telehealth |
| Everolimus | Rapalog (better oral bioavailability) | Oncology, transplant, TSC-associated indications | Investigated for immune function in older adults; no aging endpoint used |
PEARL: the only randomised trial, and what it actually found
PEARL is the trial cited most often as proof rapamycin works in humans. It was a 48-week, decentralised, double-blind, placebo-controlled study of intermittent compounded rapamycin — 5 mg or 10 mg once weekly — in 129 healthy, normatively-aging adults.
PEARL at a glance
| Detail | Finding |
|---|---|
| Design | 48-week, randomised, double-blind, placebo-controlled, decentralised |
| N | 129 healthy adults, 5 mg or 10 mg weekly vs placebo |
| Primary endpoint | Visceral adiposity by DXA — no change (η² = 0.001, p = 0.942) |
| Safety objective | Met — comparable adverse events across groups over a year |
| Positive findings | Sex- and dose-stratified secondary outcomes, partly self-reported |
| Sponsor | AgelessRx — a telehealth company that sells rapamycin |
The rest of the human evidence base
- No trial has ever used a clinical aging outcome — disability, multimorbidity, mortality — as a primary endpoint for rapamycin in humans. Every trial to date uses a surrogate.
- RESTOR (NCT06658093, n=194, recruiting) is a dose-finding pharmacokinetic study — the groundwork that arguably should have preceded widespread off-label use, not followed it.
- A separate observational study (NCT06550271, n=67) exists specifically because compounded rapamycin's bioavailability differs from the FDA-approved generic — meaning people taking the compounded version don't reliably know their own exposure.
How people actually take it off-label
There is no approved longevity dose, because there is no approved longevity indication. What exists is a widely-repeated pattern borrowed from PEARL — the only human RCT — and from the intermittent-dosing hypothesis originally proposed to reduce the immunosuppressive risk of continuous dosing used in transplant patients.
What PEARL actually tested — not a recommendation
| Dose | Frequency | What it showed |
|---|---|---|
| 5 mg | Once weekly | No change in visceral adiposity vs placebo; tolerable over 48 weeks |
| 10 mg | Once weekly | No change in visceral adiposity vs placebo; tolerable over 48 weeks |
Rapamycin is an immunosuppressant — that's not incidental
Rapamycin's FDA approval is for preventing organ-transplant rejection by suppressing the immune response. That is the same mechanism being repurposed for longevity, and it does not become side-effect-free because the person taking it doesn't have a transplant. Every known risk below follows directly from deliberately dampening mTOR-driven immune and repair pathways in someone who has no medical need to.
Known risks, off-label longevity use
| Risk | Why it happens | What it means in practice |
|---|---|---|
| Immunosuppression | The approved mechanism — it's designed to suppress immune response | Reduced ability to fight infection; live vaccines are contraindicated |
| Impaired wound healing | mTORC1 drives the cell growth wound repair depends on | Relevant before any planned surgery or dental work |
| Hyperlipidaemia | Common, dose-related effect of mTOR inhibition | Needs monitoring, especially alongside existing cardiovascular risk |
| Mouth ulcers (stomatitis) | Common, dose-related | Usually the first sign someone notices; often prompts dose reduction |
| Glucose intolerance | mTOR inhibition affects insulin signalling | Relevant for anyone with pre-diabetes or a metabolic risk profile |
The honest bottom line
Ranked on: fit for a stated situation, given the current evidence — not a recommendation to start. The only human RCT missed its primary endpoint; everything below assumes that is understood going in.
| # | Option | Verdict | Grade |
|---|---|---|---|
| 1 | You're healthy with no aging-drug trial access | Wait, or discuss with a prescriber who knows your full history | — |
| 2 | You have any planned surgery, dental work, or active infection | Not now | — |
| 3 | You're already on other medications | Get your stack checked before anything else | — |
| 4 | You're a transplant patient already on prescribed sirolimus | This page isn't about you | — |
- 01
You're healthy with no aging-drug trial access
Wait, or discuss with a prescriber who knows your full historyThe mouse data is genuinely compelling; the human data isn't there yet. Starting an immunosuppressant on mouse evidence alone, outside a monitored trial, is accepting real risk for an unproven benefit.
- 02
You have any planned surgery, dental work, or active infection
Not nowImpaired wound healing and immunosuppression are established, mechanism-driven risks — not hypothetical ones — and they apply regardless of what the longevity data eventually shows.
- 03
You're already on other medications
Get your stack checked before anything elseRapamycin's interaction profile is substantial. This is the first question a pharmacist asks, and it should be the first question you ask before considering a compounded prescription from a telehealth form.
- 04
You're a transplant patient already on prescribed sirolimus
This page isn't about youYou're on it for an approved indication, under monitoring. The off-label longevity question addressed here doesn't apply to your situation.
Frequently asked questions
Does rapamycin actually extend human lifespan?
It hasn't been shown to. PEARL, the only 48-week randomised placebo-controlled trial in healthy adults, ran 129 people on 5 mg or 10 mg weekly and found no change in its primary endpoint of visceral adiposity (p = 0.942). It met its safety objective — low-dose intermittent rapamycin appears tolerable over a year — which is a real finding, but a different one from proving it slows aging. Its positive secondary results were sex- and dose-stratified and partly self-reported, and the trial's sponsor sells rapamycin.
Is rapamycin safe for longevity use?
PEARL found it tolerable over 48 weeks at 5–10 mg weekly in healthy adults, with adverse events comparable to placebo. That is not the same as safe with no caveats: rapamycin is an approved immunosuppressant, and it carries known risks — impaired wound healing, hyperlipidaemia, mouth ulcers, glucose intolerance, and reduced infection resistance — that apply to anyone taking it, trial data or not. It is also frequently taken as a compounded product with different bioavailability from the studied drug, which adds a dosing unknown on top of the drug's own risk profile.
What rapamycin dosage is used for longevity?
There is no approved longevity dose. The pattern most often cited comes from PEARL, the only human RCT: 5 mg or 10 mg once weekly. That is what was studied in that trial, not a recommendation — dosing should be set by a prescriber who knows your full medical history and current medications, not copied from a trial protocol.
Is rapamycin an immunosuppressant?
Yes — that is its FDA-approved mechanism, used to prevent rejection in organ-transplant patients. Longevity use repurposes that same immunosuppressive action in people who have no transplant and no medical need for it, which is why the infection risk, impaired wound healing and drug-interaction profile are genuine considerations rather than fine print.
How do I talk to a doctor about taking rapamycin for aging?
Bring the PEARL trial by name (NCT04488601) rather than a general request for 'the longevity drug' — it lets a clinician see exactly what has and hasn't been shown. Disclose every other medication and supplement you take, since rapamycin's interaction profile is substantial, and be upfront that you're asking about an off-label, unproven use of an immunosuppressant rather than an approved indication.
Keep reading
- Anti-aging pharmaceuticals: what has actually been tested
Where rapamycin sits alongside senolytics, metformin and GLP-1s, graded the same way.
- Mounjaro vs Ozempic: which works better, and what it costs you
The other major off-label longevity drug category, graded with the same standard.
- Free stack check
Screen rapamycin against everything else you take before you start.
More in Anti-aging pharma
- What are the most effective antiaging prescription treatments available?
Anti-ageing prescription treatments ranked on randomised human evidence: tretinoin, botulinum toxin and fillers for visible ageing; GLP-1 agonists for metabolic ageing; statins and antihypertensives for the ageing that kills — and rapamycin, metformin, hormones and senolytics, which are prescribed for ageing without evidence for it.
- Which antiaging medicines deliver clinically proven wrinkle reduction results?
Medicines with clinically proven wrinkle reduction, ranked on randomised trials: botulinum toxin for dynamic lines, tretinoin and tazarotene for photoageing wrinkles, hyaluronic-acid fillers for folds, adapalene, then the over-the-counter retinol and peptides — and why sunscreen underwrites all of them.
- What antiaging pharmaceuticals work best for skin rejuvenation?
Anti-ageing pharmaceuticals for skin rejuvenation ranked on randomised evidence across texture, pigmentation, lines and volume: tretinoin, hydroquinone and tranexamic acid, botulinum toxin, fillers, azelaic acid, adapalene, oral isotretinoin (low-dose) — and the systemic drugs that do nothing for skin.
- Which doctor-prescribed antiaging drugs are safest long term?
Doctor-prescribed anti-ageing drugs ranked on long-term safety data: statins and antihypertensives (decades, millions), topical tretinoin, menopausal HRT in the window, GLP-1 agonists (years), metformin off-label, low-dose rapamycin, senolytics, testosterone 'optimisation' and growth hormone — with what is actually known about each over years.
- How do I choose a medical-grade antiaging treatment plan?
A ranked method for choosing a medical-grade anti-ageing treatment plan: measure first, treat what is measured, prefer on-label evidence, separate skin from systemic, demand monitoring, price the plan honestly — and the clinic-menu features that mean it is not medical-grade at all.
- What antiaging medications should I discuss with my dermatologist?
The anti-ageing medications worth raising with a dermatologist, ranked by how much the prescription adds over what you can buy: tretinoin, hydroquinone and tranexamic acid, neuromodulators and fillers, tazarotene, azelaic acid, low-dose isotretinoin — and what to bring to the appointment.